Plain-English translation of NCT01730781 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →This study uses a special type of brain imaging called PET scanning with a radioactive tracer called OMAR to measure cannabinoid receptors in the brain. Cannabinoid receptors are naturally present in everyone's brain, and researchers want to understand how they may differ in people with conditions like schizophrenia, cannabis dependence, trauma, opioid use disorder, and other psychiatric conditions. By studying these differences, scientists hope to better understand how the brain works in these conditions.
Researchers believe that cannabinoid receptors in the brain may play a role in psychiatric and addiction disorders, but we don't yet fully understand how they work or how they change in different conditions. This study aims to fill that gap by directly imaging and measuring these receptors in people with different diagnoses.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you will come to Yale University for one or more PET brain imaging scans. If you are in the cannabis dependence group, you will have at least three scans: one while using cannabis as usual, one after 48 hours without cannabis, and one after four weeks without it. Other groups may have one scan or multiple scans depending on medication status or other factors. Each visit involves lying still in a imaging scanner for a period of time while the radioactive tracer allows researchers to visualize your brain's cannabinoid receptors.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States